Ligand Pharmaceuticals has been granted a patent for compounds and methods in the fields of chemistry and medicine. The patent includes the use of heterocycle amines to treat inflammatory disorders and a method of preparing a specific compound. GlobalData’s report on Ligand Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Ligand Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Ligand Pharmaceuticals's grant share as of September 2023 was 42%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11773110B2) discloses a method for preparing a compound of Formula (IV). The method involves the use of a 2-halopyridine as a starting material and performing a coupling reaction in the presence of a palladium catalyst and a base.
The patent claims specify various options for the structure of the 2-halopyridine, including specific substituents and functional groups. Additionally, the claims describe the possible structures for R1 and R4, which are substituents on the compound of Formula (IV). R1 can be NR7R8, CH2NR7R8, or an optionally substituted C1-C6 alkyl, with specific preference given to NR7R8 or CH2NR7R8. R4 can be an optionally substituted heteroaryl selected from C3-C6 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, and specific heteroaryl groups such as pyridine, pyrazole, pyridazine, and pyrimidine. R4 can also be substituted with 1-2 substituents selected from C1-C6 alkyl and CN. Specific examples of R4 include cyano, triazolyl, oxazolyl, isoxazolyl, imidazoyl, pyridyl, pyrazolyl, pyrimidinyl, pyridazinyl, and C1-C6 alkyl, with preference given to pyridyl and pyrazolyl. The most preferred option for R4 is pyrazolyl.
The patent also mentions that the compound of Formula (IV) can be selected from a group of compounds, although the specific compounds in this group are not provided in the claims.
In summary, the granted patent describes a method for preparing a compound of Formula (IV) using a 2-halopyridine as a starting material and performing a coupling reaction in the presence of a palladium catalyst and a base. The patent claims provide various options for the structure of the 2-halopyridine, as well as the substituents on the compound of Formula (IV), including R1 and R4. The patent also mentions a group of compounds that can be obtained using this method.
To know more about GlobalData’s detailed insights on Ligand Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
